前列腺特异性抗原筛查根据健康专业咨询和年龄在美国。

IF 2.3 Q3 ONCOLOGY Prostate Cancer Pub Date : 2022-01-06 eCollection Date: 2022-01-01 DOI:10.1155/2022/8646314
Ray M Merrill, Seth A Otto, Eliza B Hammond
{"title":"前列腺特异性抗原筛查根据健康专业咨询和年龄在美国。","authors":"Ray M Merrill,&nbsp;Seth A Otto,&nbsp;Eliza B Hammond","doi":"10.1155/2022/8646314","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>In 2018, the US Preventive Services Task Force recommended that PSA screening for prostate cancer involve men aged 55-69, based on a personal decision following consultation with a health professional. PSA screening in men aged 70 or older should only occur if symptoms exist. This study identifies the association between having a PSA test in the past two years and whether or not there was consultation with a health professional about the benefits and/or harms of PSA screening.</p><p><strong>Methods: </strong>Analyses were based on data involving men aged 40 years or older, who responded to PSA related questions in the 2018 BRFSS survey.</p><p><strong>Results: </strong>Approximately 32.0% (14.6% for ages 40-54, 41.7% for ages 55-69, and 49.8% for ages 70 years and older) of respondents had a PSA test in the past two years. Approximately 81.7% of these men had talked with a health professional about the benefits and/or harms of PSA screening, with 42.4% having discussed the benefits and harms, 54.6% having discussed the benefits only, and 3.0% having discussed the harms only. The odds of a PSA test in the past two years in men having talked with a health professional about the benefits and harms of the test versus no talk are 10.1 (95% CI 9.3-10.8), in men who talked with a health professional about the benefits only versus no talk are 10.8 (95% CI 10.0-11.6), and in men who talked with a health professional about the harms only versus no talk are 3.9 (95% CI 2.9-5.1).</p><p><strong>Conclusion: </strong>PSA screening is most common in men aged 70 or older, which is counter to the US Preventive Task Force recommendation. Most men having a PSA test have talked with a health professional about the test, but the talks tended to focus on just the benefits of screening and not both potential benefits and harms.</p>","PeriodicalId":20907,"journal":{"name":"Prostate Cancer","volume":null,"pages":null},"PeriodicalIF":2.3000,"publicationDate":"2022-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8758274/pdf/","citationCount":"1","resultStr":"{\"title\":\"Prostate-Specific Antigen Screening According to Health Professional Counseling and Age in the United States.\",\"authors\":\"Ray M Merrill,&nbsp;Seth A Otto,&nbsp;Eliza B Hammond\",\"doi\":\"10.1155/2022/8646314\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>In 2018, the US Preventive Services Task Force recommended that PSA screening for prostate cancer involve men aged 55-69, based on a personal decision following consultation with a health professional. PSA screening in men aged 70 or older should only occur if symptoms exist. This study identifies the association between having a PSA test in the past two years and whether or not there was consultation with a health professional about the benefits and/or harms of PSA screening.</p><p><strong>Methods: </strong>Analyses were based on data involving men aged 40 years or older, who responded to PSA related questions in the 2018 BRFSS survey.</p><p><strong>Results: </strong>Approximately 32.0% (14.6% for ages 40-54, 41.7% for ages 55-69, and 49.8% for ages 70 years and older) of respondents had a PSA test in the past two years. Approximately 81.7% of these men had talked with a health professional about the benefits and/or harms of PSA screening, with 42.4% having discussed the benefits and harms, 54.6% having discussed the benefits only, and 3.0% having discussed the harms only. The odds of a PSA test in the past two years in men having talked with a health professional about the benefits and harms of the test versus no talk are 10.1 (95% CI 9.3-10.8), in men who talked with a health professional about the benefits only versus no talk are 10.8 (95% CI 10.0-11.6), and in men who talked with a health professional about the harms only versus no talk are 3.9 (95% CI 2.9-5.1).</p><p><strong>Conclusion: </strong>PSA screening is most common in men aged 70 or older, which is counter to the US Preventive Task Force recommendation. Most men having a PSA test have talked with a health professional about the test, but the talks tended to focus on just the benefits of screening and not both potential benefits and harms.</p>\",\"PeriodicalId\":20907,\"journal\":{\"name\":\"Prostate Cancer\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.3000,\"publicationDate\":\"2022-01-06\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8758274/pdf/\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Prostate Cancer\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1155/2022/8646314\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2022/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q3\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Prostate Cancer","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/2022/8646314","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 1

摘要

背景:2018年,美国预防服务工作组建议年龄在55-69岁之间的男性进行前列腺癌PSA筛查,这是基于与健康专业人员咨询后的个人决定。70岁或以上的男性只有在症状存在的情况下才应该进行PSA筛查。本研究确定了在过去两年内进行PSA检测与是否向健康专家咨询PSA筛查的利弊之间的联系。方法:分析基于2018年BRFSS调查中回答PSA相关问题的40岁及以上男性的数据。结果:大约32.0%的受访者(40-54岁14.6%,55-69岁41.7%,70岁及以上49.8%)在过去两年中进行过PSA检测。这些男性中约81.7%曾与健康专业人员讨论过PSA筛查的益处和/或危害,其中42.4%讨论过益处和危害,54.6%只讨论过益处,3.0%只讨论过危害。在过去两年中,与健康专业人员交谈过PSA测试的利弊与不交谈的男性进行PSA测试的几率为10.1 (95% CI 9.3-10.8),与健康专业人员交谈过PSA测试的利弊与不交谈的男性进行PSA测试的几率为10.8 (95% CI 10.0-11.6),与健康专业人员交谈过PSA测试的利弊与不交谈的男性进行PSA测试的几率为3.9 (95% CI 2.9-5.1)。结论:PSA筛查在70岁或以上的男性中最常见,这与美国预防工作组的建议相反。大多数接受PSA检测的男性都曾与健康专家讨论过这项检测,但这些讨论往往只关注筛查的好处,而不是潜在的好处和坏处。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Prostate-Specific Antigen Screening According to Health Professional Counseling and Age in the United States.

Background: In 2018, the US Preventive Services Task Force recommended that PSA screening for prostate cancer involve men aged 55-69, based on a personal decision following consultation with a health professional. PSA screening in men aged 70 or older should only occur if symptoms exist. This study identifies the association between having a PSA test in the past two years and whether or not there was consultation with a health professional about the benefits and/or harms of PSA screening.

Methods: Analyses were based on data involving men aged 40 years or older, who responded to PSA related questions in the 2018 BRFSS survey.

Results: Approximately 32.0% (14.6% for ages 40-54, 41.7% for ages 55-69, and 49.8% for ages 70 years and older) of respondents had a PSA test in the past two years. Approximately 81.7% of these men had talked with a health professional about the benefits and/or harms of PSA screening, with 42.4% having discussed the benefits and harms, 54.6% having discussed the benefits only, and 3.0% having discussed the harms only. The odds of a PSA test in the past two years in men having talked with a health professional about the benefits and harms of the test versus no talk are 10.1 (95% CI 9.3-10.8), in men who talked with a health professional about the benefits only versus no talk are 10.8 (95% CI 10.0-11.6), and in men who talked with a health professional about the harms only versus no talk are 3.9 (95% CI 2.9-5.1).

Conclusion: PSA screening is most common in men aged 70 or older, which is counter to the US Preventive Task Force recommendation. Most men having a PSA test have talked with a health professional about the test, but the talks tended to focus on just the benefits of screening and not both potential benefits and harms.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Prostate Cancer
Prostate Cancer ONCOLOGY-
CiteScore
2.70
自引率
0.00%
发文量
9
审稿时长
13 weeks
期刊介绍: Prostate Cancer is a peer-reviewed, Open Access journal that provides a multidisciplinary platform for scientists, surgeons, oncologists and clinicians working on prostate cancer. The journal publishes original research articles, review articles, and clinical studies related to the diagnosis, surgery, radiotherapy, drug discovery and medical management of the disease.
期刊最新文献
Evaluation of Second-Line Treatment for Castration-Resistant Prostate Cancer following the Administration of Upfront Androgen Receptor Signaling Inhibitors. Prostate Cancer Detection from MRI Using Efficient Feature Extraction with Transfer Learning Alterations of Sexual and Erectile Functions after Brachytherapy for Prostate Cancer Based on Patient-Reported Questionnaires Health-Related and Psychosocial Factors Associated with Prostate Cancer Stage at Diagnosis among Males Participating in Alberta’s Tomorrow Project Cognitive Dysfunction in Patients Treated with Androgen Deprivation Therapy: A Multimodality Functional Imaging Study to Evaluate Neuroinflammation.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1